PhD student position - Novel multimodal imaging agents for clinical and preclinical use | Radboud University Medical Centre

This project involves the development and optimisation of novel multimodal imaging agents for clinical and preclinical use. Your role will be to apply these particles and modify them as necessary for a broad range of applications, particularly preclinical in vivo cell tracking and targeting models. The project will involve working with various in vivo imaging techniques, including MRI, ultrasound and fluorescence.

Our group is world-renowned for cellular therapy (dendritic cell vaccinations) in melanoma patients, and the application of imaging to clinical cell tracking. Thus, we expect the imaging agents developed as part of this project to enter clinical use. The group has an excellent publication record, and you can expect to work in a friendly, cooperative environment with the freedom to design your work within this framework. This project will be fully funded by an ERC Starting grant.

Profile

The successful applicant will already have a Masters or Bachelors degree in related fields, such as biology or biotechnology. Experience with animal experiments (mice or rats) is preferred, but not required, as is experience with in vivo imaging techniques. Prior research experience, such as for a thesis project is mandatory. Very good spoken and written English is essential.

Organization

NCMLS

The Nijmegen Centre for Molecular Life Sciences in the Netherlands is a leading European research school providing an outstanding research setting for the Radboud University Nijmegen. The NCMLS focuses on basic science and its translation into pioneering treatments in the clinic. NCMLS innovations are advanced through technology platforms such as genomics, proteomics, and molecular imaging.

Department of Tumor Immunology

Research within this department aims at a better understanding of our immune system using molecular-, cell biological- and immunological- techniques and is centred around antigen presenting dendritic cells which play an important role in regulating the immune response. An important activity of the department is the translation of basic research into clinical application. In particular, the development of novel dendritic cell based vaccines to treat cancer patients.

Comments and contact information

Applicants should submit a letter of intent outlining special interest in the position; relevant qualifications, experience and career goals; a curriculum vitae; and names and addresses of at least 3 professional references.

For more information please contact Dr. Mangala Srinivas, telephone +31-(0)24-3617600, E-mail Αυτή η διεύθυνση Email προστατεύεται από τους αυτοματισμούς αποστολέων ανεπιθύμητων μηνυμάτων. Χρειάζεται να ενεργοποιήσετε τη JavaScript για να μπορέσετε να τη δείτε. (Use this E-mail address only for information. For application use the Apply button)

Application deadline is 9 October 2013.

For further information visit the website of Tumor Immunology.